Clinical trial · Observational
Routine Electronic Monitoring Of Quality Of Life -Poumon (REMOQOL-Poumon)
Impact of Routine Electronic Monitoring of Health-related Quality of Life on Care Relationship of Cancer Patients With Non-small Cell Lung Cancer, Locally Advanced or Metastatic, Systemic Treatment-naïve: a Randomized Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Routine electronic monitoring of health-related quality of life (REMOQOL) consists of collecting HRQoL patients' data via an electronic device in order to provide these data to healthcare providers. Collected data could be used by professionals to personalize care through for instance, orientation towards personalized supportive care; assessment of toxicities related to treatments or adapted treatments. The aim of this study is to investigate the impact of REMOQOL on the care relationship in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are naïve for systemic treatment. To do this, the investigators want to conduct a randomized trial at the Besançon University Hospital. Several teams are collaborating on this project: Methodology and Quality of Life Unit in Oncology (UMQVC), pneumonology and medical oncology services of the Besançon University Hospital and psychology laboratories of Franche-Comté and Burgundy Universities. The original aspects of this research are the particular interest in the care relationship between physicians and patients, also taking an interest in the physician's experience, the strong collaboration with researchers in psychology, the use of mixed quantitative and qualitative analysis techniques as well as the design of randomized study.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Electronic HRQoL questionnaires with feedback to physicians | Other | — | UNRESOLVED |
| Paper-pencil HRQoL questionnaires w.o. feedback to physicians | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Electronic HRQoL questionnaires with feedback to physicians
- description
- 40 patients allocated in this arm will answer HRQOL questionnaires using an electronic form in CHES Software. The HRQoL scores, presented as graphics, will be transmitted to physicians.
- interventionNames
- Other: Electronic HRQoL questionnaires with feedback to physicians
- label
- Paper-pencil HRQoL questionnaires w.o. feedback to physician
- description
- 40 patients allocated in this arm will answer HRQOL questionnaires using "pencil-paper", without transmission of the HRQoL scores to physicians.
- interventionNames
- Other: Paper-pencil HRQoL questionnaires w.o. feedback to physicians
Primary outcomes (1)
- measure
- quality of care relationship, assessed for patients and physicians: AREP questionnaire
- timeFrame
- Month 3
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria for patients: * Any patient diagnosed with locally advanced or metastatic non-small cell lung cancer * Patients treated at University Hospital of Besançon * No prior systemic therapy for cancer * Males and Females, age ≥18 years old * Patient able to complete the HRQoL questionnaires * Patients who gave their informed consent to participate. Inclusion Criteria for the sub cohort of patients undergoing the semi-structured interview with the researcher in psychology: * Patients who realized 4 clinical encounters with collection of HRQoL * For patients from experimental arm, the physician must have checked HRQoL results Inclusion Criteria for physicians: • Any physician treating patients included in the study REMOQOL-Poumon Exclusion Criteria: * Patients with tumor recurrence * Patients receiving oral antineoplastic therapy for whom at least monthly follow-up is not feasible * Patients with psychopathology or serious cognitive problems
References
Publications (0)
Data not yet available